Urgent

Acute myeloid leukaemia (AML) - management overview

AML · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A rapidly progressive clonal expansion of myeloid blasts causing marrow failure. Management requires urgent diagnosis, molecular/cytogenetic risk stratification, and either intensive induction chemotherapy or lower-intensity regimens with targeted agents.

Red flags

  • Coagulopathy suggesting acute promyelocytic leukaemia
  • Hyperleukocytosis with leukostasis (hypoxia, confusion)
  • Tumour lysis syndrome
  • Neutropenic sepsis
  • Rapidly rising blast count

Assessment

Differential diagnosis

  • Acute lymphoblastic leukaemia
  • Blast-phase CML
  • Myelodysplastic syndrome
  • Aplastic anaemia
  • Leukaemoid reaction
  • Acute promyelocytic leukaemia

Investigations

  • FBC, film and blast count; coagulation screen (exclude APL/DIC)
  • Bone marrow aspirate/trephine with immunophenotyping
  • Cytogenetics and molecular panel (FLT3, NPM1, IDH1/2, CEBPA, TP53)
  • Tumour lysis labs (urate, potassium, phosphate, calcium, renal function)
  • LDH, fibrinogen, LFTs
  • HLA typing and infection screen for transplant planning

Management

  • Recognise urgently - cytopenias with circulating blasts need same-day haematology
  • Exclude acute promyelocytic leukaemia immediately (coagulopathy is life-threatening and treatment differs)
  • Stabilise: transfusion support, treat sepsis, start tumour lysis prophylaxis
  • Confirm diagnosis and perform full genetic risk stratification
  • Decide intensity by fitness, age and genetics
  • For fit patients give intensive induction (anthracycline plus cytarabine, '7+3')
  • For unfit/older patients use venetoclax plus a hypomethylating agent
  • Add targeted agents where indicated (FLT3 inhibitors, IDH inhibitors, gemtuzumab for CD33+)
  • Assess remission by marrow and measurable residual disease; consolidate accordingly
  • Refer high-risk/relapsed disease for allogeneic stem cell transplant and provide intensive supportive care

Drugs & doses

Cytarabine 100-200 mg/m2/day IV continuous for 7 days plus daunorubicin 60 mg/m2 IV days 1-3 (intensive '7+3')
Venetoclax (ramp-up to 400 mg PO daily) plus azacitidine 75 mg/m2 SC/IV days 1-7 (lower intensity)
Midostaurin/quizartinib for FLT3-mutated; allopurinol or rasburicase for tumour lysis prophylaxis
Broad-spectrum antimicrobials for neutropenic sepsis

Disposition

Immediate admission to a haematology/oncology centre; intensive supportive care; transplant referral for high-risk disease.

Complications & pitfalls

  • Neutropenic sepsis
  • Tumour lysis syndrome
  • DIC (especially APL)
  • Leukostasis
  • Treatment-related marrow aplasia and organ toxicity
  • Relapse

Exam pearls

  • Always exclude APL first - its coagulopathy kills early and ATRA is urgent
  • Molecular genetics now drive both prognosis and targeted therapy choice
  • Venetoclax-azacitidine has transformed outcomes for older unfit patients
  • Measurable residual disease guides transplant decisions
  • Start tumour lysis prophylaxis before cytoreduction

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.